Citations

Showing 10 of 108104 citations.

p53 upregulated by HIF-1α promotes hypoxia-induced G2/M arrest and renal fibrosis in vitro and in vivo
Liu, Limin , Zhang, Peng , Bai, Ming , He, Lijie , Zhang, Lei , Liu, Ting , Yang, Zhen , Duan, Menglu, Liu, Minna , Liu, Baojian , Du, Rui , Qian, Qi , Sun, Shiren , Liu, Ting

Mayo Clinic

Journal of Molecular Cell Biology | July 18, 2018 | Volume: 11 | Issue: 5 | Pages: 371-382

10.1093/jmcb/mjy042 | PMID 30032308 Get It

Abstract Hypoxia plays an important role in the genesis and progression of renal fibrosis. The underlying mechanisms, however, have not been sufficiently elucidated. We examined the role of p53 in hypoxia-induced renal fibrosis in cell culture (human and rat renal tubular epithelial cells) and a mouse unilateral ureteral obstruction (UUO) model. Cell cycle of tubular cells was determined by flow cytometry, and the expression of profibrogenic factors was determined by RT-PCR, immunohistochemistry, and western blotting. Chromatin immunoprecipitation and luciferase reporter experiments were performed to explore the effect of HIF-1α on p53 expression. We showed that, in hypoxic tubular cells, p53 upregulation suppressed the expression of CDK1 and cyclins B1 and D1, leading to cell cycle (G2/M) arrest (or delay) and higher expression of TGF-β, CTGF, collagens, and fibronectin. p53 suppression by siRNA or by a specific p53 inhibitor (PIF-α) triggered opposite effects preventing the G2/M arrest and profibrotic changes. In vivo experiments in the UUO model revealed similar antifibrotic results following intraperitoneal administration of PIF-α (2.2 mg/kg). Using gain-of-function, loss-of-function, and luciferase assays, we further identified an HRE3 region on the p53 promoter as the HIF-1α-binding site. The HIF-1α–HRE3 binding resulted in a sharp transcriptional activation of p53. Collectively, we show the presence of a hypoxia-activated, p53-responsive profibrogenic pathway in the kidney. During hypoxia, p53 upregulation induced by HIF-1α suppresses cell cycle progression, leading to the accumulation of G2/M cells, and activates profibrotic TGF-β and CTGF-mediated signaling pathways, causing extracellular matrix production and renal fibrosis.
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
Johnson, Douglas B. , Bordeaux, Jennifer , Kim, Ju Young, Vaupel, Christine, Rimm, David L. , Ho, Thai H. , Joseph, Richard W. , Daud, Adil , Conry, Robert M. , Gaughan, Elizabeth , Hernandez‐Aya, Leonel F. , Funchain, Pauline , Smithy, James W. , Witte, John S. , McKee, Svetlana B., Wrangle, John M., Dabbas, Bashar , Tangri, Shabnam, Lameh, Jelveh, Hall, Jeffrey M., Markowitz, Joseph , Balko, Justin M. , Dakappagari, Naveen, Daud, Adil I , Smithy, James , Ko, Jennifer , Wrangle, John M , Ho, Thai , Funchain, Pauline , Rimm, David , Dimou, Anastasios , Ko, Jennifer S.

Mayo Clinic

Clinical Cancer Research | July 18, 2018 | Volume: 24 | Issue: 21 | Pages: 5250-5260

10.1158/1078-0432.ccr-18-0309 | PMID 30021908 Get It

Abstract Purpose: PD-1/L1 axis–directed therapies produce clinical responses in a subset of patients; therefore, biomarkers of response are needed. We hypothesized that quantifying key immunosuppression mechanisms within the tumor microenvironment by multiparameter algorithms would identify strong predictors of anti–PD-1 response. Experimental Design: Pretreatment tumor biopsies from 166 patients treated with anti–PD-1 across 10 academic cancer centers were fluorescently stained with multiple markers in discovery (n = 24) and validation (n = 142) cohorts. Biomarker-positive cells and their colocalization were spatially profiled in pathologist-selected tumor regions using novel Automated Quantitative Analysis algorithms. Selected biomarker signatures, PD-1/PD-L1 interaction score, and IDO-1/HLA-DR coexpression were evaluated for anti–PD-1 treatment outcomes. Results: In the discovery cohort, PD-1/PD-L1 interaction score and/or IDO-1/HLA-DR coexpression was strongly associated with anti–PD-1 response (P = 0.0005). In contrast, individual biomarkers (PD-1, PD-L1, IDO-1, HLA-DR) were not associated with response or survival. This finding was replicated in an independent validation cohort: patients with high PD-1/PD-L1 and/or IDO-1/HLA-DR were more likely to respond (P = 0.0096). These patients also experienced significantly improved progression-free survival (HR = 0.36; P = 0.0004) and overall survival (HR = 0.39; P = 0.0011). In the combined cohort, 80% of patients exhibiting higher levels of PD-1/PD-L1 interaction scores and IDO-1/HLA-DR responded to PD-1 blockers (P = 0.000004). In contrast, PD-L1 expression was not predictive of survival. Conclusions: Quantitative spatial profiling of key tumor-immune suppression pathways by novel digital pathology algorithms could help more reliably select melanoma patients for PD-1 monotherapy. Clin Cancer Res; 24(21); 5250–60. ©2018 AACR.
Implementing electronic patient-reported outcomes measurements: challenges and success factors
Nordan, Lisa, Blanchfield, Lorrie, Niazi, Shehzad K. , Sattar, Juliet, Coakes, Courtney Elizabeth, Uitti, Ryan J. , Vizzini, Michael, Naessens, James M. , Spaulding, Aaron , Niazi, Shehzad, Uitti, Ryan, Spaulding, Aaron

Mayo Clinic

BMJ Quality & Safety | July 18, 2018 | Volume: 27 | Issue: 10 | Pages: 852-856

10.1136/bmjqs-2018-008426 | PMID 30021802 Get It

Splenic torsion: a rare cause of abdominal pain
Mohseni, Michael , Kruse, Brian, Graham, Charley, Kruse, Brian T, Mohseni, Michael M

Mayo Clinic

BMJ Case Reports | July 18, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2018-224952

10.1136/bcr-2018-224952 | PMID 30021736 Get It

Splenic torsion is an exceedingly rare but clinically important disease process that should be recognised promptly by the treating physician. In this condition, there is twisting of the spleen along its vascular pedicle, subsequently leading to abdominal pain in the setting of organ ischaemia. Vascular thrombosis and splenic infarction may ensue. Torsion has been described in cases of a known wandering spleen. Abnormal development of the splenic suspensory ligaments may predispose a patient to a wandering spleen. Treatment of splenic torsion is typically surgical, with goals of preservation of the spleen if possible. We present a case of a young woman who presented with left-sided chest and abdominal pain and was found to have splenic torsion with complete splenic infarction. Surgical intervention was required, and splenectomy was performed. In this case presentation, we outline the multidisciplinary approach needed to care for the patient with this rare condition.
Timing of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor Initiation and Allograft Vasculopathy Progression and Outcomes in Heart Transplant Recipients
Briasoulis, Αlexandros , Pereira, Naveen L. , Boilson, Barry A. , Edwards, Brooks S., Adigun, Rosalyn , Maltais, Simon, Daly, Richard C. , Kushwaha, Sudhir S. , Asleh, Rabea , Briasoulis, Alexandros , Lerman, Amir

Mayo Clinic

ESC Heart Failure | July 18, 2018 | Volume: 5 | Issue: 6 | Pages: 1118-1129

10.1002/ehf2.12329 | PMID 30019530 Get It

Abstract Aims Early studies from the 1990s have shown that statins improve survival and attenuate cardiac allograft vasculopathy (CAV). However, little contemporary data are available on the incremental benefit of statins with the current use of new-generation immunosuppressive agents and the use of coronary intravascular ultrasound for assessment of CAV. We sought to investigate the effect of early statin (ES) as compared with late statin (LS) initiation after heart transplantation (HT) on long-term CAV progression and clinical outcomes in a large contemporary HT cohort. Methods and results We analysed a cohort of 409 adult HT recipients. CAV progression was assessed by serial coronary intravascular ultrasound volumetric measurements of the differences between baseline and last follow-up plaque volume (PV) and plaque index (PV/vessel volume ratio). CAV progression and clinical outcomes were compared between the ES (<2 years after HT) and the LS (>2 years after HT) groups. During a median follow-up of 8.2 years, ES resulted in significantly lower change (Δ) of plaque index (+3.8% ± 1.7% vs. +8.2% ± 3.6%; P = 0.0008) and PV (+0.8 ± 0.3 vs. +1.9 ± 1.2; P = 0.045) compared with LS group. In a Cox proportional hazards regression model and after adjustment for baseline characteristics, ES was associated with a 52% decreased risk of CAV-associated events (hazard ratio 0.48, 95% confidence interval: 0.27–0.91; P = 0.025) and a 42% decreased risk of the composite endpoint of all-cause mortality and CAV-associated events (hazard ratio 0.58, 95% confidence interval: 0.38–0.91; P = 0.019). Conclusions Early initiation of statin therapy after HT results in attenuated CAV progression as well as in decreased CAV-related events and mortality.
Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma
Garzón-Muvdi, Tomás , Rogers, Davis , Lim, Michael , Gallia, Gary L. , Weingart, Jon , Brem, Henry , Chaichana, Kaisorn L. , Ehresman, Jeff , Bettegowda, Chetan

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | July 18, 2018 | Volume: 80 | Issue: 01 | Pages: 059-066

10.1055/s-0038-1667066 | PMID 30733902 Get It

Object Meningiomas occur in various intracranial locations. Each location is associated with a unique set of surgical nuances and risk profiles. The incidence and risk factors that predispose patients to certain deficits based on tumor locations are unclear. This study aimed to determine which preoperative factors increase the risk of patients having new deficits after surgery based on tumor location for patients undergoing intracranial meningioma surgery. Methods Adult patients who underwent primary, nonbiopsy resection of a meningioma at a tertiary care institution between 2007 and 2015 were retrospectively reviewed. Stepwise multivariate logistic regression analyses were used to identify associations with postoperative deficits based on tumor location. Results Postoperatively, from the 761 included patients, there were 39 motor deficits (5.1%), 23 vision deficits (3.0%), 19 language deficits (2.5%), 27 seizures (3.5%), and 26 cognitive deficits (3.4%). The factors independently associated with any postoperative deficits were preoperative radiation (hazard ratio [HR] [95% confidence interval, CI] 3.000 [1.346–6.338], p = 0.008), cerebellopontine angle tumors (HR [95% CI] 2.126 [1.094–3.947], p = 0.03), Simpson grade 4 resections (HR [95% CI] 2.000 [1.271–3.127], p = 0.003), preoperative motor deficits (HR [95% CI] 1.738 [1.005–2.923], p = 0.048), preoperative cognitive deficits (HR [95% CI] 2.033 [1.144–3.504], p = 0.02), and perioperative pulmonary embolisms (HR [95% CI] 11.741 [2.803–59.314], p = 0.0009). Conclusion Consideration of the factors associated with postoperative deficits in this study may help guide treatment strategies for patients with meningiomas.
The murine dialysis fistula model exhibits a senescence phenotype: pathobiological mechanisms and therapeutic potential
Nath, Karl A. , O’Brien, Daniel R. , Croatt, Anthony J., Grande, Joseph P. , Ackerman, Allan W., Nath, Meryl C. , Kirkland, James L. , Katušić, Zvonimir S. , Yamada, Satsuki , Tchkonia, Tamara, Terzic, André , Tchkonia, Tamar

Mayo Clinic

American Journal of Physiology-Renal Physiology | July 18, 2018 | Volume: 315 | Issue: 5 | Pages: F1493-F1499

10.1152/ajprenal.00308.2018 | PMID 30019935 Get It

There is no therapy that promotes maturation and functionality of a dialysis arteriovenous fistula (AVF). The search for such therapies largely relies on evaluation of vascular responses and putative therapies in experimental AVFs. We studied an AVF in mice with chronic kidney disease (CKD). We demonstrate numerous stressors in the vein of the AVF-CKD group, including pathological shear, mitogenic, inflammatory, and hypoxia-reoxygenation stress. Because stress promotes premature senescence, we examined whether senescence is induced in the vein of the AVF-CKD model. We demonstrate a senescence phenotype in the AVF-CKD model, as indicated by increased expression of p16Ink4a, p21Cip1, and p53 and expected changes for certain senescence-associated microRNAs. RNA-sequencing analysis demonstrated differential expression of ~10,000 genes, including upregulation of proinflammatory and proliferative genes, in the vein of the AVF-CKD group. The vein in the AVF-CKD group exhibited telomere erosion and increased senescence-associated β-galactosidase activity and staining. Senescence was induced in the artery of the AVF-CKD group and in the vein of the AVF without CKD. Finally, given the rapidly rising clinical interest in senolytics, we provide proof of concept of senolytics as a therapeutic approach by demonstrating that senolytics decrease p16Ink4a expression in the AVF-CKD model. This study introduces a novel concept underlying the basis for maturational and functional failure in human dialysis AVFs and identifies a new target for senolytic therapy.
Epigenome Editing Enters the Arena. A New Tool to Reveal (and Reverse?) Pathologic Gene Regulation
Tan, Qi , Tschumperlin, Daniel J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 18, 2018 | Volume: 198 | Issue: 5 | Pages: 549-551

10.1164/rccm.201807-1239ed | PMID 30016116 Get It

Serum free light chain measurements to reduce 24‐h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein
Tschautscher, Marcella , Rajkumar, S. Vincent , Lacy, Martha Q. , Gertz, Morie A. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Stephen R., Lust, John A., Russell, Stephen J. , Kapoor, Pranshant, Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Kaddoura, Marcella , Rajkumar, S Vincent , Lacy, Martha, Gertz, Morie A , Hwa, Lisa, Zeldenrust, Stephen, Lust, John, Russell, Stephen, Leung, Nelson , Go, Ronald S , Gonsalves, Wilson , Warsame, Rahma , Russell, Stephen J , Dingli, David , Lin, Yi , Dispenzieri, Angela , Buadi, Francis K. , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.

Mayo Clinic

American Journal of Hematology | July 17, 2018 | Volume: 93 | Issue: 10 | Pages: 1207-1210

10.1002/ajh.25215 | PMID 30016549 Get It

AbstractDetection of myeloma progression (PD) relies on serial 24‐h urinary M protein measurements in patients without measurable serum M spike. We examined whether serial difference free light chain (dFLC) levels could be used as a surrogate for serial 24‐h urine M protein measurements in monitoring for PD in patients with baseline measurable urine M protein. We studied 122 patients who had serial measurement of urine M protein and serum FLC and had demonstrated PD. The median increase in dFLC with progression as defined by urine M spike was 110% (IQR: 55‐312) and median absolute increase was 74 mg/dL; while 89% of patients had dFLC increase ≥ 25%, 94% had absolute increase in dFLC > 10 mg/dL, and 98% met at least 1 of these 2 criteria at PD. In patients with baseline measurable serum FLC (n = 118), 89% had increase in dFLC ≥ 25%, 97% had dFLC increase of > 10 mg/dL, and 98% had 1 of the 2. We conclude that serial dFLC assessments can be used in place of serial 24‐h urine protein assessments during myeloma surveillance to monitor for PD. Once patients have an absolute increase in dFLC of >10 mg/dL from the nadir, a 24‐h urine collection can then be assessed to document PD as per the International Myeloma Working Group criteria.
Paradigm Shifts in Nocturnal Glucose Control in Type 2 Diabetes
Basu, Ananda , Joshi, Nisha, Carter, Rickey E. , Rizza, Robert A., Basu, Rita , Carter, Rickey E , Miles, John J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 17, 2018 | Volume: 103 | Issue: 10 | Pages: 3801-3809

10.1210/jc.2018-00873 | PMID 30020503 Get It

Abstract Context A better understanding of nocturnal regulation of glucose homeostasis will provide the framework for designing rational therapeutic strategies to improve the management of overnight glucose in patients with type 2 diabetes (T2D). Objective To establish the nocturnal pattern and regulation of glucose production (EGP) in humans and to determine whether the pattern is dysregulated in people with T2D. Design Subjects were infused with [3-3H] glucose overnight. Arterial blood samples were drawn for hormones and analytes to estimate EGP throughout the night. Deuterium-labeled water was provided to measure gluconeogenesis (GNG) using the hexamethylenetetramine method of Landau. Setting Mayo Clinic Clinical Research Trials Unit, Rochester, MN, USA. Participants and Interventions A total of 43 subjects [23 subjects with T2D and 20 nondiabetic (ND) subjects comparable for age and body mass index] were included in this study. Main Outcome(s) Measure(s) Glucose and EGP. Results Plasma glucose, C-peptide, and glucagon concentrations were higher throughout the night, whereas insulin concentrations were higher in subjects with T2D vs ND subjects at 1:00 and 4:00 am but similar at 7:00 am. EGP was higher in the subjects with T2D than in the ND subjects throughout the night (P < 0.001). Glycogenolysis (GGL) fell and GNG rose, resulting in significantly higher (P < 0.001) rates of GNG at 4:00 and 7:00 am and significantly (P < 0.001) higher rates of GGL at 1:00, 4:00, and 7:00 am in T2D as compared with ND. Conclusions These data imply that optimal therapies for T2D for nocturnal/fasting glucose control should target not only the absolute rates of EGP but also the contributing pathways of GGL and GNG sequentially.